Turnstone charts $75M IPO for TIL cell therapies in drumroll of biotech IPOs this month

Turn­stone Bi­o­log­ics plans to list on the Nas­daq in a $75 mil­lion raise short­ly af­ter a trio of biotechs — Apogee Ther­a­peu­tics, Sagimet Bio­sciences and 60 De­grees Phar­ma­ceu­ti­cals — went pub­lic fol­low­ing a stretch of in­ac­tiv­i­ty for the be­lea­guered sec­tor.

The sol­id tu­mor cell ther­a­py biotech hopes to mark a turn­around af­ter los­ing key deals with Ab­b­Vie in 2021 and Take­da in 2022 and en­act­ing lay­offs last year.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN